Silo Pharma Collaborates on Innovative Ketamine Implant Device

Silo Pharma Collaborates on Innovative Ketamine Implant Device

Prototype development and feasibility testing underway for optimized subcutaneous delivery

Silo Pharma, Inc. (NASDAQ: SILO), recognized for its developmental stage biopharmaceutical initiatives, has taken a significant step in pain management therapies through a recent collaboration with Kymanox. This partnership focuses on the specialized design and development of an advanced subcutaneous insertion device for SP-26, a groundbreaking ketamine-loaded implant aimed at treating fibromyalgia and chronic pain.

The agreement entails Kymanox spearheading an initial proof-of-concept design phase, which is crucial for the advancement of the device. Following this, comprehensive prototype and feasibility testing will be conducted to identify the optimal insertion depth for the device within tissue.

“Our initial analytical testing and proof-of-concept extrusion trials have affirmed the most effective formulation for our SP-26 implants. This collaboration moves us towards developing a unique insertion device, slated for preclinical studies to validate its efficacy,” expressed Silo’s CEO, Eric Weisblum. “We are thrilled with the progress we are making with our ketamine implants intended to deliver sustained relief from chronic pain.”

As part of the preclinical research strategy, particular attention is being placed on ensuring SP-26 meets all safety parameters required by FDA guidelines for potential at-home therapeutic use. The successful approval of this device could mark a pivotal moment, positioning SP-26 as the first injectable ketamine-based therapeutic accessible for home use.

Understanding SP-26 and Its Potential

SP-26 is designed as an injectable dissolvable polymer implant, providing innovative approaches in treating chronic pain and fibromyalgia. This pioneering subcutaneous implant is tailored to deliver the ketamine medication in a controlled manner, managing dosage and ensuring a time-released effect for effective pain relief. If clinical trials confirm its success, SP-26 could navigate the FDA's streamlined 505(b)(2) regulatory pathway for drug approval, simplifying the journey to market access.

Collaboration with Kymanox

In tandem with the SP-26 collaboration, Kymanox is also supporting Silo Pharma as a regulatory partner for SPC-15. This treatment specifically targets stress-induced affective disorders, including PTSD, which represents a critical aspect of Silo’s broader mission to address neglected therapeutic areas.

About Silo Pharma and Its Mission

Silo Pharma Inc. (NASDAQ: SILO) is at the forefront of developing novel therapeutics that address various underserved medical conditions. Their focus spans across stress-related psychiatric disorders, chronic pain management, and a range of central nervous system (CNS) diseases. Silo is devoted to innovating both traditional therapies as well as psychedelic treatments, integrating cutting-edge formulations and effective delivery systems.

The company’s lead program, SPC-15, is an intranasal solution designed to tackle PTSD and anxiety associated with stress. Additionally, SP-26 complements their strategy as a time-release implant aimed at chronic pain and fibromyalgia relief.

Innovative Research and Development Approaches

Silo Pharma’s commitment to pushing boundaries in pharmaceutical development is underscored by their preclinical programs, including SPC-14, which targets Alzheimer’s disease treatments, and SPU-16— a peptide designed to target and combat multiple sclerosis. These efforts are propelled by collaborative engagements with universities and independent laboratories, enhancing their research capabilities and fostering innovative breakthroughs.

Frequently Asked Questions

What is the SP-26 device developed by Silo Pharma?

The SP-26 is a ketamine-loaded implant designed for subcutaneous delivery, targeting chronic pain and fibromyalgia.

Who is Kymanox?

Kymanox is a specialized partner collaborating with Silo Pharma for the design and development of the SP-26 insertion device.

What are the potential benefits of SP-26?

If successful, SP-26 may provide sustained pain relief and could be positioned as the first injectable ketamine therapeutic for home use.

How does Silo Pharma conduct its research?

Silo’s research involves collaborations with universities and labs to enhance the development of their therapeutic programs.

What other programs does Silo Pharma focus on?

Along with SP-26, Silo Pharma is developing SPC-15 for stress disorders and other innovative treatments for CNS diseases.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.